You will now be redirected to the GD3 website
Genesis Drug Discovery & Development is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.
Learn more about GD3Disease Modeling
Disease Models
Animal models are critical in the selection and development of novel therapeutics. Studies evaluating exposure, tolerability, dose-exposure linearity, bioavailability, and efficacy in a sentinel screening model are often used when selecting a lead clinical candidate. Further insight into the therapeutic potential of a compound can be gained through scheduling and combination studies and the exploration of additional disease models. The likelihood of clinical success can be increased through an early understanding of the mechanism of action, PK-PD relationship, metabolism, toxicology and the development of biomarkers and a translational path.
The GD3 team of model development and execution experts has worked on diverse models spanning oncology, inflammation and autoimmunity, metabolism, obesity and diabetes, behavioral and other disease areas. With our broad skill set, we can implement novel models tailored to your program's needs. We've worked with many routes or administration and a wide variety of test agents.
Learn more about